Over-the-Counter Medicines
Eldoral Cap.
- Product Category
- Antitussive expectorant
- Active Ingredients
- Erdostein
- Appearance
- A hard capsule with a green cap and yellow body, containing white to milky-white crystalline powder.
- Reimbursement Code
- 648105090
01 / 02
1. Ingredient content
Of 1 capsule
- Active ingredient: Erdostein (in-house specification) ································································································································································ in 300mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: light anhydrous silicic acid, magnesium stearate, capsule, talc
2. Effectiveness
Mucolysis and expectoration in acute and chronic respiratory diseases
3. Dosage and dosage
Adults: As erdosteine, 300 mg is administered orally 2-3 times a day.
When administering for acute respiratory disease, do not administer for more than 10 consecutive days.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Patients with liver cirrhosis and patients with cystathionine-synthase deficiency (metabolites of this drug may interfere with methionine metabolism).
3) Peptic ulcer patients
4) Patients with severe renal impairment (creatinine clearance <25 mL/min)
5) Patients with severe liver impairment
6) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) Patients with mild to moderate hepatic impairment (No increase in adverse reactions due to this drug was observed, but the dose of this drug should not exceed 300 mg per day.)
2) This medicine contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
3. Adverse reactions
1) Overdosage (more than 1200 mg per day) may cause sweating, dizziness, and flushing.
2) Nervous system: headache
3) Respiratory system: cold, difficulty breathing
4) Digestive system: abnormal taste, nausea, vomiting, diarrhea, epigastric pain, abdominal pain, heartburn
5) Skin: Hives, erythema, eczema
6) Domestic post-marketing surveillance results (Number of investigated cases: 3,303 for capsules, 791 for syrups) The adverse reactions reported are as follows, and it is unclear whether they are related to this drug. : Fatigue, indigestion, abdominal pain, gastrointestinal disorder, diarrhea, vomiting, headache, rash, erythema nodosum, palpitations, facial edema, whole body edema, itching, lethargy, dazedness, rash.
4. Interaction
Particular caution should be exercised when expectorants are administered in combination with cough medicine, as they may increase the risk of bronchial infection and cause bronchospasm due to difficulty expelling phlegm from the bronchial tubes due to cough relief.
5. Administration to pregnant and lactating women
In animal experiments, no direct or indirect toxicity was found with respect to conception, embryonic development of the fetus, or postpartum development. However, the safety of administration during pregnancy or lactation has not been established, so it is advisable not to administer to pregnant women, women who may be pregnant, or lactating women.
6. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 300 capsules/bottle
7. Period of use
36 months from date of manufacture
Of 1 capsule
- Active ingredient: Erdostein (in-house specification) ································································································································································ in 300mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: light anhydrous silicic acid, magnesium stearate, capsule, talc
2. Effectiveness
Mucolysis and expectoration in acute and chronic respiratory diseases
3. Dosage and dosage
Adults: As erdosteine, 300 mg is administered orally 2-3 times a day.
When administering for acute respiratory disease, do not administer for more than 10 consecutive days.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Patients with liver cirrhosis and patients with cystathionine-synthase deficiency (metabolites of this drug may interfere with methionine metabolism).
3) Peptic ulcer patients
4) Patients with severe renal impairment (creatinine clearance <25 mL/min)
5) Patients with severe liver impairment
6) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) Patients with mild to moderate hepatic impairment (No increase in adverse reactions due to this drug was observed, but the dose of this drug should not exceed 300 mg per day.)
2) This medicine contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
3. Adverse reactions
1) Overdosage (more than 1200 mg per day) may cause sweating, dizziness, and flushing.
2) Nervous system: headache
3) Respiratory system: cold, difficulty breathing
4) Digestive system: abnormal taste, nausea, vomiting, diarrhea, epigastric pain, abdominal pain, heartburn
5) Skin: Hives, erythema, eczema
6) Domestic post-marketing surveillance results (Number of investigated cases: 3,303 for capsules, 791 for syrups) The adverse reactions reported are as follows, and it is unclear whether they are related to this drug. : Fatigue, indigestion, abdominal pain, gastrointestinal disorder, diarrhea, vomiting, headache, rash, erythema nodosum, palpitations, facial edema, whole body edema, itching, lethargy, dazedness, rash.
4. Interaction
Particular caution should be exercised when expectorants are administered in combination with cough medicine, as they may increase the risk of bronchial infection and cause bronchospasm due to difficulty expelling phlegm from the bronchial tubes due to cough relief.
5. Administration to pregnant and lactating women
In animal experiments, no direct or indirect toxicity was found with respect to conception, embryonic development of the fetus, or postpartum development. However, the safety of administration during pregnancy or lactation has not been established, so it is advisable not to administer to pregnant women, women who may be pregnant, or lactating women.
6. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 300 capsules/bottle
7. Period of use
36 months from date of manufacture